{
    "nctId": "NCT00820547",
    "briefTitle": "Efficacy and Tolerance Study of Bevacizumab in Her2- Inflammatory Breast Cancer Patients",
    "officialTitle": "Phase II Study Evaluating the Efficacy and Tolerance of Bevacizumab (Avastin) in HER2- Inflammatory Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "Complete histologic response rate",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed inflammatory breast cancer, meeting 1 of the following staging criteria:\n\n  * T4d, any N (AJCC stage IIIB or IIIC)\n  * Gustave-Roussy Institute (IGR) classification Poussee evolutirie (PEV; measures tumor growth over time) 2\n\n    * PEV 2: tumor with underlying breast tissue, especially skin, that is affected by subacute inflammation and edema involving \\< \u00bd of breast surface\n  * IGR classification PEV 3\n\n    * PEV 3: acute or subacute inflammation and edema involving \\> \u00bd of breast surface\n  * Biopsy-confirmed presence of tumor embolism in surface lymph nodes\n* HER2-negative (HER2 0 or 1+, or HER2 2+ by IHC if FISH-negative allowed)\n* No metastatic disease\n* No non-inflammatory breast cancer with edema, ulceration, or satellite skin nodules\n* No bilateral breast cancer\n* Hormone receptor status known\n\nPATIENT CHARACTERISTICS:\n\n* Any menopausal status allowed\n* WHO performance status 0-2\n* Life expectancy \u22653 months\n* LVEF normal by ECHO\n* ANC \\>1.5 x 10\\^9/L\n* Platelet count \\>100 x 10\\^9/L\n* INR \u22641.5 (except for patients on prophylactic anticoagulants)\n* aPTT \u22641.5 times upper limit of normal (ULN)\n* Total bilirubin normal\n* SGOT and SGPT \u22641.25 times ULN\n* Alkaline phosphatase \u22642.5 times ULN\n* Creatinine clearance \u226560 mL/min\n* Proteinuria \\<2+ or 24-hour urine protein \u22641 g\n* No unhealed wound, stomach ulcer, or bone fracture\n* No history of thrombotic or hemorrhagic disorders\n* No significant cardiovascular disease including the following:\n\n  * Cerebrovascular accident within the past 6 months\n  * Unstable angina\n  * Cardiac failure\n  * Myocardial infarction\n  * Arrhythmia requiring treatment\n* No uncontrolled hypertension (i.e., systolic BP \\>150 mm Hg and/or diastolic BP \\>100 mm Hg)\n* No other active infection or serious illness that would preclude patient from receiving study treatment\n* No hypersensitivity to any active products or excipients of study drugs\n* Not pregnant or nursing\n* Fertile patients must use effective contraception during and for 6 months after completion of study treatment\n* No social or psychologic reasons that would prevent study compliance or follow-up\n* No patients who are incarcerated or on probation\n\nPRIOR CONCURRENT THERAPY:\n\n* No prior chemotherapy, radiotherapy, or hormonal therapy for this disease\n* More than 4 weeks since prior surgery (diagnostic biopsy or installation of implant allowed)\n* More than 10 days since prior chronic non-inflammatory steroids (e.g., acetylsalicylic acid \\>325 mg/day) or platelet anticoagulation treatment (e.g., dipyridamole, ticlopidine, clodiprogel, cilostazol)\n* More than 10 days since prior oral or parenteral anticoagulant or thrombolytic drugs (preventative thrombolytic drugs allowed)\n* No concurrent participation in another experimental clinical trial",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}